Radical Catheter Technologies, a NeuroTechnology Investors (NTI) portfolio company, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Radical 076 and 064 Reperfusion Catheters. The clearance marks an important expansion of the company’s patented catheter platform beyond neurovascular access and delivery into devices intended for revascularization of patients suffering from an acute ischemic stroke caused by a large vessel occlusion.

“Catheter design has remained largely the same for 35 years. By shifting the design paradigm and thinking differently, Radical has developed a portfolio that dramatically changes what is possible in both neurovascular access and therapy,” said Martin Dieck, Chairman and co-founder of Radical Catheter Technologies. “We will continue to execute on our vision to build a comprehensive neurovascular platform that supports physicians from access to outcomes.”

The reperfusion catheters build on Radical’s patented ribbon-based technology, which is designed to combine flexibility, stability and durability in challenging neurovascular anatomy. The company’s existing access catheters help physicians navigate to treatment sites and deliver therapeutic devices, and the new reperfusion devices extend the portfolio into mechanical thrombectomy, a therapy that restores blood flow by removing a clot that is occluding the blood vessel in the brain.

“I’ve relied on the Radical access catheters for their trackability and support, so I was eager to try the new reperfusion catheter,” said Benjamin Yim, MD, Neurosurgeon at John Muir Medical Center in Walnut Creek, Calif. “The catheter tracked smoothly through tortuous anatomy, and I achieved complete revascularization on the first pass. It’s a natural extension of the platform, from access to reperfusion.”

The new clearance follows the FDA clearances of Radical’s 6F, 7F, and 8F neurovascular access catheters, which have already demonstrated unparalleled clinical performance. Radical will showcase the company’s new reperfusion catheters along with its complete family of access catheters at the Society of Vascular and Interventional Neurology (SVIN) Annual Meeting, November 18–20, 2026 in Las Vegas. At Radical’s booth (#111), physicians can assess the catheter’s trackability and navigability in a challenging neuro simulation model.

Radical’s suite of catheters have demonstrated success in a majority of clinical cases performed. The advantages of Radical’s catheters are emphasized in those cases that have traditionally been considered difficult. Because of Radical’s impressive performance, the catheters are becoming the first-line choice for many physicians. The benefit of reliable access removes the need for a complex combination of devices and the risk of needing to change catheters in the middle of a procedure while enhancing efficiency throughout the intervention.

In building upon its impressive competitive advantage, Radical is also forming commercialization partnerships with other trailblazing neurovascular companies that have developed complementary technologies. Radical’s specialized commercialization group supports these visionary entities such as Serenity Medical and Borvo Medical (both NTI portfolio companies). Through these partnerships, Radical is building an innovation powerhouse that supports access, delivery, and treatment across complex procedures.

About Radical Catheter Technologies
Radical Catheter Technologies is a neurovascular medical technology company commercializing a patented, ribbon-based catheter platform. The platform combines flexibility, pushability, and stability in a single construct, and now spans FDA-cleared access and reperfusion catheters for treatment of acute ischemic stroke. The company’s commercial team, Radical Solutions, also supports complementary technology from fellow NeuroTechnology Investors (NTI) portfolio companies, giving neurovascular specialists a broad, integrated portfolio to advance minimally invasive neurological care for patients. Learn more at https://radicalcatheter.com or follow us on LinkedIn.

About NeuroTechnology Investors (NTI)
NeuroTechnology Investors (NTI) is a leading investment group dedicated to advancing breakthrough neurological technologies in the medical device sector, with a diverse portfolio that includes companies such as Synchron, Radical Catheter Technologies, Borvo Medical, and Serenity Medical. Established in 2016 and headquartered in Mountain View, California, NTI investors bring extensive clinical expertise to accelerate portfolio growth and improve patient access to transformative clinical solutions. Learn more at https://themdadvantage.com or follow us on LinkedIn.

Media gallery

About The Author